We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Several generic companies have come up short in their attempt to get into the Oxycontin and Risperdal market due to two court rulings announced Oct. 16.
Dr. Reddy’s Laboratories will begin distributing an authorized generic version of GlaxoSmithKline’s (GSK) migraine drug Imitrex in late 2008, under terms of a patent settlement.
Shire Pharmaceuticals announced Andrx has filed an application to market a generic version of Shire’s attention-deficit/hyperactivity disorder (ADHD) drug Adderall XR.
Repercussions from the failed Plavix settlement continue at Bristol-Myers Squibb (BMS), with the apparently forced departure of CEO Peter Dolan and Senior Vice President and General Counsel Richard Willard on the recommendation of a federal monitor.
Barr Pharmaceuticals, faced with generic competition to its birth-control drug Seasonale after an unsuccessful attempt for a patent reissue, launched an authorized generic Sept. 7 — the day Watson Pharmaceuticals received final FDA approval to market its version.
The U.S. International Trade Commission (ITC) has decided not to review a decision made earlier this year that Roche’s importation and use of its experimental anemia drug Mircera in the U.S. did not violate Amgen’s patents on its anemia drug Epogen.